CER 1236
Alternative Names: CER-1236Latest Information Update: 08 May 2024
At a glance
- Originator CERo Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; Phagocyte stimulants; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia; Haematological malignancies; Solid tumours
Most Recent Events
- 30 Apr 2024 Preclinical trials in Acute myeloid leukaemia in USA (Parenteral) prior to April 2024
- 30 Apr 2024 Pharmacodynamic data from preclinical trials in Acute myeloid leukemia released by CERo Therapeutics
- 08 Mar 2024 Pharmacokinetics data from a preclinical trial in Acute myeloid leukemia released by CERo Therapeutics